MAPT and Alzheimer disease: The main goal of this feasibility study is not to differentiate between populations with or without AD, rather, it is to identify for the first time the spectral signatures of retinal Aβ42 and pS396-Tau and compare to previous signatures of retinal Aβ deposits.